Hannah Wuellner
Acute Care · Saint Louis, MONPI 1245977040
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 24.0% of the total.
Across 48 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$271
- Boehringer Ingelheim$203
- Grifols USA, LLC$107
- Actelion Pharmaceuticals US, Inc.$100
- Insmed, Inc.$81
- Regeneron Healthcare Solutions, Inc.$73
- plus $295 from 11 others
What the payments were for
- Food & beverage$1,131100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $271 |
| Boehringer Ingelheim | 7 | $203 |
| Grifols USA, LLC | 4 | $107 |
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Insmed, Inc. | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $73 |
| AbbVie | 2 | $45 |
| Verona Pharma, Inc. | 2 | $42 |
| United Therapeutics Corporation | 2 | $41 |
| Baxter Healthcare | 1 | $29 |
| GSK | 2 | $27 |
| Lilly USA, LLC | 1 | $24 |
| Sanofi | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,131 in reported general payments places this provider in the 75th percentile of 272 acute care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $289,576 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 272 | $201,146 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 109 | $81,448 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 126 | $62,949 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $28,712 |
| EliquisApixaban | 44 | $23,148 |
| Advair HfaFluticasone Propion/Salmeterol | 57 | $21,991 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $20,133 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 75 | $16,974 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $12,852 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $12,530 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,819 |
| Arnuity ElliptaFluticasone Furoate | 29 | $6,899 |
| DuleraMometasone/Formoterol | 19 | $6,123 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $6,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $203 | $328,10686 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $27 | $308,185518 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $271 | $100,365163 claims |
| PfizerEliquis | $15 | $23,14844 claims |
| MerckDulera | $14 | $6,12319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 272 acute care providers in Missouri.
Other acute care in Saint Louis
- Jennifer ReganSaint Louis$5K
- Kayla TourvilleSaint Louis$5K
- Christa SinkSaint Louis$5K
- Shalu LamaSaint Louis$3K
- Emily GavinSaint Louis$3K
- Brittany ZellerSaint Louis$3K
- Molly HulsenSaint Louis$2K
- Patricia ClarkSaint Louis$2K
- Paula VaughnSaint Louis$2K
- Jennifer BurnsSaint Louis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.